Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

143.93

-0.78 (0.54%)

as of Sep 11, 2026, 8:00:00 pm Market Open.

311 watching

PAST TOP PICK

(A Top Pick July 12/04. Down 40%.) Sold out before the big drop.

BUY

Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.

DON'T BUY

Took a tremendous hit with their withdrawal of Vioxx. Buying it now would be bottom fishing. A lot of issues going on in the pharma sector now. Weak pipeline.

DON'T BUY

Has declined because of a recall of one of their drugs. Will probably have a bounce.

PAST TOP PICK

(A Top Pick Apr 28/04. Down 4%.) Had bought for the wrong reasons. Bought at the top of a cycle as a defensive play. Don't buy.

TOP PICK

Dividend yield is very attractive. You pay very little for the upside.

TOP PICK

Yield is over 3%. Trading around 15 X next year's earnings.

TOP PICK

This late in the cycle, look for stocks that are large, overlooked and underowned. Had a low in 2002 and a higher low at the end of 2003 in a downtrend, still expects to see money going to this group.

WEAK BUY

Have more patent issues than the majority of the big pharmas. Not a lot of catalysts. If you are a real long-term, patient investor, not a bad buy.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up.

DON'T BUY

Still under a major downtrend line. Trying to find a base.

TOP PICK

A quiet stock in that not many people are expecting much from them, 7/8% growth this year but you do get a nice 3%+ dividend yield while you wait. Trades at about 15 X earnings. Has a new cholesterol drug coming out this year.

BUY

Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.

TOP PICK

trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%

DON'T BUY

Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.

Showing 256 to 270 of 310 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)